Sandoz Group Ag S/Adr (SDZNY) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, ladies and gentlemen, and welcome to the Sandoz call today. I will now pass on to Craig Marks, head of investor relations, for his opening remarks. Thank you. Welcome to the Sandoz Q1 sales update. Earlier today, we published a press release and an accompanying presentation on our website, which will follow on today's call. You can find these documents at sandoz.com strokeinvestors. Joining me on today's call are Richard Saylor, Chief Executive Officer, and Remco Steenbergen, Chief Financial Officer. Please turn to slide two. Our sales announcement, presentation, and discussion include forward-looking statements. Please see our disclaimer here. Please turn to slide three. Richard will begin today's presentation with a summary of the highlights in the quarter, followed by an update on the business. Remco will cover the sales performance as well as full year guidance. Following the wrap-up of the presentation, we'll be happy to take your questions. With that, I will now hand over to Richard. Please turn to slide four. Thank you, Craig, and hello, everybody. It's a pleasure to welcome you all to today's call, and I'm looking forward to talking you through our continued progress. Please turn to slide five. There are four key messages I'd like you to take away from this morning. Firstly, the quarter one sales performance was in line with our expectations, meaning we've now delivered 14 consecutive courses of top-line growth. This reconfirms our growing track record of execution and performance. Secondly, we again delivered double-digit growth in biosimilars in the quarter, ahead of more launches later this year, putting us in an excellent position to produce good results in 2025. The new confirmed U.S. tariffs have been absorbed within our four-year guidance...